Myocardial Infarction

News Myocardial Infarction

• Nominations for the European Inventor Award 2010

  Twelve candidates from nine countries are competing this year for the European Inventor Award 2010, a highly regarded innovation prize presented annually by the EPO together with the European Commission to honour outstanding inventions. The prize, which is purely symbolic and involves no material re more

• New chemical imaging technique could help in the fight against atherosclerosis, suggests research

  A new chemical imaging technique could one day help in the fight against atherosclerosis, suggests research published in the August 2009 edition of the Journal of the Royal Society Interface. Atherosclerosis is the disease underlying most heart attacks and strokes and it is characterised by lesions more

• Borgo Olona acquires Borealis’ business and operations in Castellanza, Italy

  Borealis announced that it has reached an agreement for the sale of its business and operations in Castellanza, Italy, (AMI – Italy) to Borgo Olona, a group of investors well known in the region. The new owner has decided to rename the company Chemisol Italia Srl. AMI Agrolinz Melamine Internationa more

Publications Myocardial Infarction

• Structural Alterations of Lamin A Protein in Dilated Cardiomyopathy

  Lamin A protein, encoded by the LMNA gene, belongs to the type V intermediate filament protein family and is a major nuclear protein component of higher metazoan organisms, including humans. Lamin A along with B-type lamins impart structural rigidity to the nucleus by forming a lamina that is closel more

• PM 2.5 [Core Concepts]

  High levels of air pollution in Beijing contain a large quantity of PM 2.5. © iStockPhoto.com/beijingstory. We know that air pollution is bad for your lungs, but some 20 years ago researchers made the surprising and consequential finding that fine-particle pollution can also affect your heart, causi more

• Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions

  The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis‐mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the prevention and treatment of these conditions have more

Websites Myocardial Infarction